Is Adlai Nortye Ltd. (ANL) a Buy, Sell, or Hold?
Adlai Nortye Ltd.
NASDAQ:ANL
$10.63 USD
$1.43 (15.54%)
- Volume
- 136.07K
- Average Volume
- 270.88K
- Market Capitalization
- $564.24M
- P/E Ratio
- -6.56
- Dividend Yield
- 0.00%
- Price Target
- $26.00
- Year High
- $17.25
- Year Low
- $0.88
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.65
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Yang Lu |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ANL |
| CUSIP | 00704R109 |
| CIK | 0001944552 |
| Web | https://www.adlainortye.com |
| Phone | 848 230 7430 |
| Currency | USD |
| Employees | 109 |
| Country | KY |
Liquidity
| Debt-to-Equity Ratio | -3.17 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.65 |
| Quick Ratio | 0.65 |
| Cash Ratio | 0.57 |
Sales & Book Value
| Annual Sales | $5M |
| Price / Sales | 112.85 |
| Cash Flow | -1.74 |
| Price / Cash Flow | -30.47 |
| Price / Book | -13.62 |
Price Target and Rating
| Average Stock Price Forecast | $26.00 |
| High Stock Price Forecast | $32.00 |
| Low Stock Price Forecast | $20.00 |
| Forecast Upside/Downside | -59.12% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$3.33 |
| Trailing P/E Ratio | -6.56 |
| PEG Ratio | -0.11 |
| P/E Growth | -0.11 |
| Net Income | -$35.53M |
| Net Margin | -343.86% |
| Pretax Margin | -343.86% |
| Return on Equity | 591.30% |
| Return on Assets | -49.93% |
Financials Score
| AltmanZ Score | -15.69 |
| Piotroski Score | 1.00 |
| Working Capital | -14.74M |
| Total Assets | 34.43M |
| Ebit | -45.77M |
| Market Cap | 564.24M |
| Total Liabilities | 42.76M |
Poll Results
About Adlai Nortye Ltd. (NASDAQ:ANL) Stock
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite st ... able colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
2026-07-13 07:00:00
SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito.
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
2026-05-20 13:01:16
Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
2026-05-11 10:56:18
Adlai Nortye Ltd. Sponsored ADR (ANL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
2026-04-28 10:43:36
Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
2026-04-16 07:00:00
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses.
Frequently Asked Questions
-
What is the current Adlai Nortye Ltd. (ANL) stock price?
-
Adlai Nortye Ltd.(NASDAQ:ANL) stock price is $10.63 in the last trading session. During the trading session, ANL stock reached the peak price of $17.25 while $0.879 was the lowest point it dropped to. The percentage change in ANL stock occurred in the recent session was 15.54% while the dollar amount for the price change in ANL stock was $1.43.
-
ANL's industry and sector of operation?
-
The NASDAQ listed ANL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ANL?
-
Zhiyong Yu | Vice President of Operations
Xiaofeng Ye | Chief Financial Officer
Ngai Chiu Tse | President & Head of Research & Development
Nanhai He | Head of Discovery
Donghui Yang | Chairman of the Greater China Region -
How many employees does ANL have?
-
Number of ANL employees currently stands at 109. ANL operates from Ugland House, Grand Cayman, None KY1-1104, KY.
-
Link for ANL official website?
-
Official Website of ANL is: https://www.adlainortye.com
-
How do I contact ANL?
-
ANL could be contacted at phone #848 230 7430 and can also be accessed through its website. ANL operates from Ugland House, Grand Cayman, None KY1-1104, KY.
-
How many shares of ANL are traded daily?
-
The average number of ANL shares traded daily for last 3 months was 270.88K.
-
What is the market cap of ANL currently?
-
The market value of ANL currently stands at $564.24M with its latest stock price at $10.63